Panelists discuss how progressive pulmonary fibrosis (PPF) and idiopathic pulmonary fibrosis (IPF), though distinct in etiology, share a common trajectory of irreversible lung scarring and ...

A genetic condition, cystic fibrosis changes the fluids that coats the body’s tubes and ducts, especially in the lungs. Instead of thin and slippery, they become thick and sticky, plugging up ...

PURPOSE NSF is a cutaneous and systemic disorder characterized by widespread tissue fibrosis. Although the exact physiopathology is still unknown, emergence of NSF has been strongly linked with ...

Once-weekly semaglutide 2.4 mg significantly reduced steatohepatitis and liver fibrosis symptoms among adults with metabolic dysfunction-associated steatohepatitis and moderate or advanced liver ...

Nephrogenic systemic fibrosis can cause a thickening and hardening of the skin, heart and lungs—and cause painful contracting of the joints.

Newly uncovered mechanism could drive next-gen cystic fibrosis treatments Date: March 13, 2025 Source: The Hospital for Sick Children Summary: Protein clustering mechanism on the cell membrane ...

Boehringer Ingelheim has cemented the potential of its idiopathic pulmonary fibrosis (IPF) drug with a second phase 3 win in a related lung disease leading the drugmaker to expand the indications ...

Here's what cystic fibrosis is, what causes it and how it's usually treated once it has been diagnosed.

Low doses of glucocorticoids added to immunosuppression yield no significant benefit for skin fibrosis in early diffuse cutaneous systemic sclerosis, according to data published in Arthritis Care ...

Box 1 Differential diagnoses for nephrogenic fibrosing dermopathy/nephrogenic systemic fibrosis. Scleromyxedema Systemic sclerosis Eosinophilic fasciitis Pretibial myxedema Eosinophilia–myalgia ...

Sionna has inked a deal with AbbVie to add three clinical-phase candidates to its burgeoning pipeline of cystic fibrosis prospects.